Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abroad, Academia, Academy, accomplished, Adjunct, AdventRx, advice, advisor, affiliate, affirmative, alliance, Analyst, Analytical, Anatomy, APCO, Arvid, assuming, attended, auditor, aware, banking, Barbara, barrier, Baxter, Bayer, Berkeley, billed, Biochemist, Biochemistry, biographical, biology, Bioscience, bone, Bowdoin, Boyer, Bryn, budget, capacity, career, Carlsson, Catholic, CEO, cerebrovascular, chaired, chemistry, client, CNS, Colemanbecame, College, Connecticut, conserve, Consilium, Council, counselor, CSO, Cymbalta, deferral, Denmark, Deputy, description, Detroit, DHM, diagnostic, discretion, dismissal, dismissed, Distinguished, distributor, Diversified, divided, division, Dohmen, Duke, duty, editorial, eighteen, electronically, employed, Engineering, entirety, entity, entry, equitable, Europaea, exceed, expert, faculty, faith, Fellow, fellowship, fiduciary, final, Ford, Fordham, forfeiture, formula, Francisco, Fullerton, gathering, Genzyme, George, German, Gerontology, Glaxo, grew, grossed, GSK, GW, hardship, Harry, Haskell, heading, headquartered, Henry, Honorary, Hospice, Imitrex, improper, Indemnification, indemnify, Indiana, injury, insight, Interneuron, internship, Irene, Island, Japan, joined, joining, journal, Kidder, Lamictal, letter, liable, Lieber, Ligand, Los, loyalty, Lund, Lundbeck, Mansbach, Mawr, Mayflower, member, Michigan, Minnesota, misconduct, Mission, modern, monetary, mortgage, Nancy, NASA, neurobiology, Neurochemistry, neuropharmaceutical, neuropsychopharmacology, newly, nominee, Nuada, Ohmeda, Oregon, Osteologix, owner, pain, Parion, Pasadena, Paul, Peabody, Pennsylvania, permanently, permissible, permission, Pfizer, Pharmacia, pharmacist, pharmacy, Philosophy, Physician, pleasure, Polytechnic, preceding, Princeton, Prize, procedure, proceed, promulgated, Prozac, Prudential, Psychobiology, Psychogeriatric, psychopharmacologic, Psychopharmacology, Purdue, purport, Questcor, Ramsey, ranking, recipient, reclassification, reelected, relief, relocate, relocation, replenish, residence, residency, retention, retirement, revision, Revocable, Rhode, rose, Royal, San, Sandoz, Santa, Satellite, satisfaction, Scholar, Science, scope, sought, southern, speaker, specialty, spent, spouse, spread, St, standing, Steven, Straterra, subsidy, subspecialty, suitable, Supergen, Supply, Swedish, Symbyax, teaching, Tensor, TL, Trustmark, unaudited, Union, unlawful, unvested, Upjohn, USA, Vector, venture, verification, voluntarily, waived, Washington, Wellcome, Wesleyan, Western, Wharton, wholesaler, withholding, Wooster, World, Yale, Zyprexa
Filing tables
Filing exhibits
- 10-K Annual report
- 10.88 Form of Notice of Grant of Stock Options
- 10.89 Stock Ownership Policy
- 21 Subsidiaries of Registrant
- 23.1 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
- 23.2 Consent of Haskell White LLP, Independent Registered Public Accouting Firm
- 31.1 Certification of Chief Executive Officer - Section 302
- 31.2 Certification of Chief Financial Officer - Section 302
- 32 Certification Pursuant to 18 U.s.c. Section 1350 - Section 906
Related press release
RSPI similar filings
Filing view
External links
EXHIBIT 32
Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002
Roger G. Stoll, Ph.D., President and Chief Executive Officer of Cortex Pharmaceuticals, Inc. (the “Company”), and Maria S. Messinger, Chief Financial Officer of the Company, each certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:
(1) | the Transition Report on Form 10-K of the Company for the transitional six-month period ended December 31, 2004 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: March 21 , 2005 | /s/ ROGER G. STOLL | |||
Roger G. Stoll, Ph.D. Chairman, President and Chief Executive Officer | ||||
Dated: March 21, 2005 | /s/ MARIA S. MESSINGER | |||
Maria S. Messinger Vice President, Chief Financial Officer and Secretary |